Pyridam Farma
Market Cap
Rp529.7b
Last Updated
2021/05/11 10:20 UTC
Data Sources
Company Financials
Executive Summary
PT Pyridam Farma Tbk develops, produces, and sells pharmaceuticals, vitamins, supplements, and traditional herbal care products in Indonesia. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with solid track record.
Share Price & News
How has Pyridam Farma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PYFA is not significantly more volatile than the rest of ID stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: PYFA's weekly volatility has decreased from 13% to 7% over the past year.
Market Performance
7 Day Return
-7.9%
PYFA
0.4%
ID Pharmaceuticals
0.1%
ID Market
1 Year Return
342.0%
PYFA
21.6%
ID Pharmaceuticals
27.1%
ID Market
Return vs Industry: PYFA exceeded the ID Pharmaceuticals industry which returned 20.4% over the past year.
Return vs Market: PYFA exceeded the ID Market which returned 22.3% over the past year.
Shareholder returns
| PYFA | Industry | Market | |
|---|---|---|---|
| 7 Day | -7.9% | 0.4% | 0.1% |
| 30 Day | -3.9% | -3.5% | -1.8% |
| 90 Day | -2.0% | -8.2% | -4.4% |
| 1 Year | 342.0%342.0% | 23.9%21.6% | 31.4%27.1% |
| 3 Year | 437.7%426.6% | 5.9%-0.02% | 7.5%-0.6% |
| 5 Year | 783.7%753.4% | 33.7%21.1% | 38.5%21.7% |
Long-Term Price Volatility Vs. Market
How volatile is Pyridam Farma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Pyridam Farma undervalued compared to its fair value and its price relative to the market?
25.79x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: PYFA (IDR990) is trading above our estimate of fair value (IDR60.89)
Significantly Below Fair Value: PYFA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PYFA is poor value based on its PE Ratio (25.8x) compared to the ID Pharmaceuticals industry average (25x).
PE vs Market: PYFA is poor value based on its PE Ratio (25.8x) compared to the ID market (22.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PYFA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PYFA is overvalued based on its PB Ratio (3.8x) compared to the ID Pharmaceuticals industry average (2.4x).
Future Growth
How is Pyridam Farma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
18.4%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pyridam Farma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Pyridam Farma performed over the past 5 years?
30.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PYFA has high quality earnings.
Growing Profit Margin: PYFA's current net profit margins (8%) are higher than last year (3.6%).
Past Earnings Growth Analysis
Earnings Trend: PYFA's earnings have grown significantly by 30.2% per year over the past 5 years.
Accelerating Growth: PYFA's earnings growth over the past year (126.4%) exceeds its 5-year average (30.2% per year).
Earnings vs Industry: PYFA earnings growth over the past year (126.4%) exceeded the Pharmaceuticals industry 9%.
Return on Equity
High ROE: PYFA's Return on Equity (14.6%) is considered low.
Financial Health
How is Pyridam Farma's financial position?
Financial Position Analysis
Short Term Liabilities: PYFA's short term assets (IDR124.5B) exceed its short term liabilities (IDR36.9B).
Long Term Liabilities: PYFA's short term assets (IDR124.5B) exceed its long term liabilities (IDR40.9B).
Debt to Equity History and Analysis
Debt Level: PYFA's debt to equity ratio (14.3%) is considered satisfactory.
Reducing Debt: PYFA's debt to equity ratio has reduced from 42.7% to 14.3% over the past 5 years.
Debt Coverage: PYFA's debt is well covered by operating cash flow (36.6%).
Interest Coverage: PYFA's interest payments on its debt are well covered by EBIT (15x coverage).
Balance Sheet
Dividend
What is Pyridam Farma current dividend yield, its reliability and sustainability?
0.40%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PYFA's dividend (0.4%) isn’t notable compared to the bottom 25% of dividend payers in the ID market (1.15%).
High Dividend: PYFA's dividend (0.4%) is low compared to the top 25% of dividend payers in the ID market (4.83%).
Stability and Growth of Payments
Stable Dividend: PYFA is not paying a notable dividend for the ID market, therefore no need to check if payments are stable.
Growing Dividend: PYFA is not paying a notable dividend for the ID market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PYFA's dividend in 3 years as they are not forecast to pay a notable one for the ID market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.0yrs
Average management tenure
CEO
Michael Handoko Soetrisno (57 yo)
20.42yrs
Tenure
Mr. Michael Handoko Boedi Soetrisno has been the President Director at PT Pyridam Farma Tbk since December 2000 and its Director since 1996. He served as Director of Manufacture at PT Pyridam Farma Tbk. He...
Leadership Team
Experienced Management: PYFA's management team is considered experienced (4 years average tenure).
Board Members
Experienced Board: PYFA's board of directors are considered experienced (6.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
PT Pyridam Farma Tbk's company bio, employee growth, exchange listings and data sources
Key Information
- Name: PT Pyridam Farma Tbk
- Ticker: PYFA
- Exchange: IDX
- Founded: 1976
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: Rp529.729b
- Shares outstanding: 535.08m
- Website: https://www.pyridam.com
Number of Employees
Location
- PT Pyridam Farma Tbk
- Ruko Villa Kebon Jeruk
- Blok F3
- Jakarta
- 11530
- Indonesia
Listings
Biography
PT Pyridam Farma Tbk develops, produces, and sells pharmaceuticals, vitamins, supplements, and traditional herbal care products in Indonesia. The company operates in two segments, Pharmaceutical Products a...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/05/11 10:20 |
| End of Day Share Price | 2021/05/10 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.